Expression of Fas and Fas-related molecules in human hepatocellular carcinoma

Human Pathology

Volumn 32, Issue 3, 2001, Pages 250-256

  Lee, Sug Hyung ^a   Shin, Min Sun ^a   Lee, Ho Sun ^a   Bae, Jeong Hoon ^a   Lee, Hun Kyung ^a   Kim, Hong Sug ^a   Kim, Su Young ^a   Jang, Ja June ^a   Joo, Mee ^a   Kang, Yun Kyung ^a   Park, Won Sang ^a   Park, Jik Young ^a   Oh, Ro Ra ^a   Han, Seo Young ^a   Lee, Jong Heun ^a   Kim, Sang Ho ^a   Lee, Jung Young ^a   Yoo, Nam Jin ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Fas; Fas ligand; Fas associated phosphatase 1; Hepatocellular carcinoma; Loss of heterozygosity; Soluble Fas

Indexed keywords

FAS ANTIGEN; FAS LIGAND; PHOSPHATASE; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0035079863     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2001.22769     Document Type: Article

References (50)

1. Double identity for proteins of Bcl-2 family
2. Apoptosis by death factor
3. Monoclonal antibody-mediated tumor regression by induction of apoptosis
4. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
5. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
6. Constitutive and induced expression of APO-1, a new member of the new grow factor/tumor necrosis receptor superfamily, in normal and neoplastic cells
7. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responses
8. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
9. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
10. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas
11. FAP-1: A protein tyrosine phosphatase that associates with Fas
12. Inhibition of Fas-induced apoptosis by Bcl-2
13. Inhibition of death receptor signals by cellular FLIP
14. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia
15. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity
16. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis
17. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis
18. Mutations in the Fas antigen in patients with multiple myeloma
19. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
20. Mutation of CD 95 (Fas/APO-1) gene in adult T-cell leukemia cells
21. Fas gene mutation in the progression of adult T cell leukemia
22. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity
23. Alterations of Fas (APO-1/CD95) gene in cutaneous malignant melanoma
24. Alterations of Fas (APO-1/CD95) gene in non-small cell lung cancer
25. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
26. Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines
27. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues
28. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
29. Resistance to Fas-mediated apoptosis in human hepatoma cells
30. The Fas system is not significantly involved in apoptosis in human hepatocellular carcinoma
31. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver
32. In vivo expression of soluble Fas and FAP-1: Possible mechanisms of Fas-resistance in human hepatoblastomas
33. Detection of soluble Fas using in situ reverse transcription-polymerase chain reaction
34. Detection of rare RNA sequences by single-enzyme in situ reverse transcription-polymerase chain reaction
35. Detection of human papillomavirus DNA in formalin fixed tissues by in situ hybridization after amplification by PCR
36. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections
37. Detection of polymorphisms within the Fas cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis
38. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene
39. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
40. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
41. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma
42. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?
43. Allelotype analysis of hepatocellular carcinoma
44. Comprehensive allelo-typing of human hepatocellular carcinoma
45. The Fas counterattack: Fas-mediated T cell killing by colon cells expressing Fas ligand
46. Gene transfer of Fas ligand induces tumor regression in vivo
47. Melanoma cell expression on Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
48. Human lung carcinomas express Fas ligand
49. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma